R&D News | pharmaphorum

News

Home

QuickFire Challenge deadline approaches for J&J BARDA Projec...

Johnson & Johnson Innovation and the Biomedical Advanced Research and Development Authority (BARDA) have announced the ‘Blue Knight Resident QuickFire Challenge: Accel

News

Lilly ends ADA on a high as obesity triple data pops

The first reveal of clinical data with Eli Lilly’s injectable triple receptor agonist for obesity suggests that the company could have a big winner on its hands if the dru

News

Lundbeck CEO Deborah Dunsire is stepping down

Lundbeck chief executive Deborah Dunsire has announced her retirement, with a replacement already lined up by the company’s board.

News

Shionogi agrees $140m deal to buy antibiotic biotech Qpex

While most pharma companies have exited the antibiotics area, Japanese dru

News

Novo Nordisk, Lilly highlight oral obesity drugs at ADA

New data from Novo Nordisk’s phase 3 trial of an oral, high-dose formulation of semaglutide reinforces its potential as a weight-loss therapy in obesity, but Eli Lilly is

News

FDA sets out its thinking on psychedelic drug trials

The FDA has published its first-ever guidance document on clinical trials with psychedelic drugs, an emerging treatment category for psychiatric and substance use disorder

QuickFire Challenge deadline approaches for J&J BARDA Projec...

Lilly ends ADA on a high as obesity triple data pops

Lundbeck CEO Deborah Dunsire is stepping down

Shionogi agrees $140m deal to buy antibiotic biotech Qpex

Novo Nordisk, Lilly highlight oral obesity drugs at ADA

FDA sets out its thinking on psychedelic drug trials

Madrigal builds in MASH with $4.4bn+ Ribo alliance

How to meet your physicians where they are online

News

Editor's Picks